Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. We believe that Masimo SET® helps clinicians monitor in excess of approximately 200 million patients in healthcare settings around the world,1 and is the primary pulse oximetry technology at 9 of the top 10 hospitals listed in the 2019-2020 U.S. News & World Report Best Hospitals Honor Roll.

Joe Kiani founded Masimo in 1989 as a private “garage start-up” company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET® Measure-through Motion* and Low Perfusion™ pulse oximetry, was shown in a study comparing three pulse oximetry technologies to demonstrate the highest sensitivity and specificity in identifying desaturation events during conditions of motion and low perfusion.